Johnson & Johnson said today it had submitted for emergency use listing of its Covid-19 vaccine to the World Health Organisation (WHO).
The company said the process is a prerequisite to supply vaccines to the Covax vaccine program co-led by WHO, which aims to deliver doses to poor and middle-income countries.
J&J entered into an agreement in December in support of the Covax program.
The company and Gavi, which also co-leads the Covax program, expect to enter into an advance purchase agreement that would provide up to 500 million doses of the single-dose vaccine to Covax through 2022, J&J said. Reuters
Copying/Pasting full or partial texts with adding very little original content are frowned upon by the community. Repeated copy/paste posts could be considered spam. Spam is discouraged by the community and may result in the account being Blacklisted.
Downvoting a post can decrease pending rewards and make it less visible. Common reasons:
Submit